Lenz Therapeutics Announced Topline Results From Phase 3 CLARITY Study Of Two Formulations Of Aceclidine, LNZ100 And LNZ101, For Presbyopia, Primary Endpoint Was Met With 71% Of Participants Achieving Three-Lines Or Greater Improvement At 3 Hours

-25.96%

LENZ Therapeutics, Inc. - Common Stock

LENZ

18.14

-25.96%

LNZ100 selected as lead candidate
Primary endpoint was met with 71% of participants dosed with LNZ100 achieving three-lines or greater improvement at 3 hours
Rapid onset and long duration shown with 71% of participants achieving three-lines or greater improvement at 30 minutes and 40% at 10 hours
New Drug Application submission anticipated in mid-2024

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.